Clinical Pharmacology and Pharmacy, 2016 (vol. 30), issue 4
Original articles
Evaluation of inquiries on drug-drug interactions in internet advisory center „I know my medicaments“
Michal Prokeš, Petr Průša, Josef Suchopár, Ondřej Suchopár
Klin Farmakol Farm. 2016;30(4):3-10 | DOI: 10.36290/far.2016.029 
Drug interactions are one of the main risks of pharmacotherapy in all developed countries of the world. Patients using multiple medications are sometimes concerned with the safety of drug-drug combinations they use. Advisory web center „I know my medicaments“ was established by AIFP to give patients basic information, whether drug-drug combinations they use are fundamentally safe or whether some risk is present. The drug lists issued by patiens to advisory center was evaluated by experts with the aid of electronic DrugAgency a. s. database of drug-drug interactions. Answers were sent back to patiens, and the drug-drug interactions, as well...
Main topic
Monoclonal antibodies in treating high cholesterol levels
Rostislav Večeřa
Klin Farmakol Farm. 2016;30(4):11-13 | DOI: 10.36290/far.2016.035
Proprotein convertase subtilisin-kexin type 9 (PCSK9) is mainly responsible for the recycling receptors for LDL particles. This results in an increase in LDL levels, which then drastically contributes to the development of atherosclerotic changes in vessel wall. This increases cardiovascular morbidity and mortality. New drugs based on monoclonal antibodies as alirocumab or evolocumab belongs amo ng PCSK9 inhibitors. Their administration leads to a dramatic reduction in LDL particles up to 50–60 %. Given that the Czech Republic ranks among the countries with high cardiovascular mortality, is introduction of these new drugs in clinical practice...
Evaluation of efficacy of anti-IgE monoclonal antibody treatment not only in severe allergic asthma
Jaromír Bystroň, Beata Hutyrová
Klin Farmakol Farm. 2016;30(4):14-18 | DOI: 10.36290/far.2016.036
The authors provide a summary of their current experience with anti-IgE antibody (omalizumab) treatment at their workplace aswell as in the Czech Republic. They report the results of studies in which omalizumab was used to treat allergic conditions otherthan severe bronchial asthma, and present findings recorded in patients monitored in the Czech Anti-IgE Registry (CAR) in theCzech Republic.
Review articles
Antiepileptic drug interactions. Part 1: Mutual interactions between antiepileptic drugs
Blanka Kořístková, Milan Grundmann
Klin Farmakol Farm. 2016;30(4):19-23 | DOI: 10.36290/far.2016.030
Pharmacokinetic interactions between antiepileptic drugs are associated with enzymatic induction or inhibition. Felbamate, clobazam,lamotrigine, stiripentol, and sulthiame are significant inhibitors. Felbamate increases the levels of clonazepam, lamotrigine,mesuximide, valproic acid, and the active S(+)-enantiomer vigabatrin. Clobazam increases the levels of stiripentol, carbamazepine,and carbamazepine-10,11-epoxide. Stiripentol increases the levels of ethosuximide, phenobarbital, carbamazepine, clobazam andN-desmethylclobazam, primidone, and valproate. Acetazolamide, felbamate, phenytoin, mesuximide, oxcarbazepine, rufinamide,
Current perspective on the role of TNFα inhibitors in treating patients with toxic epidermal necrolysis
Břetislav Lipový, Jakub Holoubek
Klin Farmakol Farm. 2016;30(4):24-27 | DOI: 10.36290/far.2016.031
Toxic epidermal necrolysis (TEN) represents the most severe syndrome of the SCARs (Severe Cutaneous Adverse Reactions) group. It is a drug-induced toxic-allergic reaction in which apoptosis develops in the area of the dermoepidermal junction. To date, the complex pathophysiological nature of this syndrome has not been elucidated reliably, which has resulted in certain confusion in the treatment. As a result, the mortality rate is still unsatisfactorily high. Given the fact that TNFα plays an important role in the hitherto described pathophysiology of TEN, the administration of TNFα inhibitors appears to be a logical choice in treating these...
Case reports
Breast cancer a chronic disease? The Anti-HER2 therapy
Markéta Pospíšková, Milan Kohoutek
Klin Farmakol Farm. 2016;30(4):28-30 | DOI: 10.36290/far.2016.032
Advanced breast cancer is up on rare cases generally incurable disease. Thanks to new knowledge about the biology of tumors,which have brought to the treatment of new therapeutic options, an significant extension of survival for this diagnosis. Mainlyinclusion of anti HER2 treatments (trastuzumab, pertuzumab, trastuzumab emtansin, lapatinib), thanks to which the OS in patientswith HER2 gene amplification extended up to 56 months. But it is still an incurable illnes sand must, in addition to the efforts toextend survival, think mainly to improve or at least maintain the quality of life of the patients.